Inform Genomics Inc. is developing its OnPART test to predict which cancer patients are most likely to have chemotherapy side effects and allow doctors to treat the unwanted effects earlier or change the chemotherapy regimens they had planned to use.

OnPART (Oncology Preferences And Risk of Toxicity) uses a chip to screen a patient's saliva against a network of SNPs associated with six common side effects of chemotherapy: nausea and vomiting, diarrhea, oral mucositis, fatigue, neuropathy and cognitive dysfunction.